Scarica l'app Stockscreener
3.14
2.48%
-0.08
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Protara Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Buy” from Brokerages - Defense World
Protara Therapeutics Reports Q1 2025 Financial Results - TipRanks
Protara Therapeutics: Q1 Earnings Snapshot - New Haven Register
Barclays PLC Takes $492,000 Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile - TipRanks
Protara (TARA) Strengthens Leadership with Key Appointments | TA - GuruFocus
Protara Therapeutics (TARA) Sees Positive Results in TARA-002 Trial | TARA Stock News - GuruFocus
Protara (TARA) Strengthens Leadership with Key Appointments | TARA Stock News - GuruFocus
Protara Therapeutics Q1 2025 Financial Results and Business Update - TradingView
Protara Therapeutics, Inc. SEC 10-Q Report - TradingView
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Geode Capital Management LLC Buys 9,553 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Renaissance Technologies LLC Sells 194,440 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Protara Therapeutics Expands Leadership Team: New CPO Receives 61,500 Equity Awards Amid Growth Push - Stock Titan
Stocks of Protara Therapeutics Inc (TARA) are poised to climb above their peers - Sete News
It would be worthwhile to take a closer look at Protara Therapeutics Inc (TARA) - uspostnews.com
Protara Therapeutics, Inc.'s (NASDAQ:TARA) institutional investors lost 14% last week but have benefitted from longer-term gains - simplywall.st
Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Sold by LPL Financial LLC - Defense World
The Potential Rise in the Price of Protara Therapeutics Inc (TARA) following insiders activity - knoxdaily.com
Biotech Co. Achieves Remarkable Cancer Treatment Results in Trial - streetwisereports.com
Protara Therapeutics Inc Inc. (TARA) Price Performance: A Technical Analysis Perspective - investchronicle.com
Balance Sheet Breakdown: Protara Therapeutics Inc (TARA)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Protara Therapeutics (NASDAQ:TARA) Given “Buy” Rating at HC Wainwright - Defense World
Protara Therapeutics stock drops following interim trial results By Investing.com - Investing.com Nigeria
Protara Therapeutics stock drops following interim trial results - Investing.com Australia
Protara Therapeutics Inc (NASDAQ: TARA)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel
Protara Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Protara Therapeutics Announces Positive Interim Results Demonstr - GuruFocus
Protara Therapeutics Shares Positive Phase 2 Interim Results Of TARA-002 In Patients With NMIBC - Nasdaq
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara Therapeutics Reports Promising Phase 2 Results for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Breakthrough Clinical Data: New Bladder Cancer Drug Shows Perfect Response Rate in Hard-to-Treat Patients - Stock Titan
3 Stocks To Watch For When Tariffs Subside - The Globe and Mail
Mountain Province Diamonds Announces Mailing of Meeting Materials For Annual and Special Meeting of Shareholders to Approve Additional Working Capital Facility - The Globe and Mail
Protara Therapeutics (TARA) to Release Quarterly Earnings on Thursday - Defense World
Protara Therapeutics Inc (TARA) gets rating Initiated from Scotiabank - knoxdaily.com
OTCQX Best 50 Virtual Investor Conference Agenda Announced for April 24th - The Globe and Mail
Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025 - The Manila Times
Protara Therapeutics to Host Conference Call on Phase 2 ADVANCED-2 Trial Data for TARA-002 in Non-Muscle Invasive Bladder Cancer - Nasdaq
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara's Bladder Cancer Drug TARA-002 Phase 2 Trial: 12-Month Efficacy Data Reveal Coming at Major Conference - Stock Titan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
No-Brainer Buy Alert: 1 Artificial Intelligence (AI) Stock With Massive Long-Term Potential - The Globe and Mail
Examining TARA’s book value per share for the latest quarter - uspostnews.com
Philip Morris (PM) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $22.50 - Defense World
Protara Therapeutics (NASDAQ:TARA) Earns Sector Outperform Rating from Analysts at Scotiabank - Defense World
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):